期刊文献+

雾化吸入布地奈德治疗慢性阻塞性肺疾病急性加重期的临床研究 被引量:5

暂未订购
导出
摘要 目的探讨足量应用雾化吸入布地奈德的临床应用价值。方法 105例慢性阻塞性肺疾病急性加重期(AECOPD)患者随机分为3组,1组予布地奈德8mg,分4次加压雾化吸入;2组予布地奈德2 mg,分2次加压雾化吸入;3组予甲泼尼龙40 mg,每日1次静脉滴注。在治疗前、治疗后3天和10天分别观察三组患者的肺功能和血气变化。结果布地奈德8 mg/d组与甲泼尼龙组均有明显改善,两组各指标改善程度相似;布地奈德2 mg/d组在治疗3天时无明显改善,治疗10天时各项指标与治疗前有差异,但改善程度较前两组低。雾化吸人布地奈德两组不良反应明显低于甲泼尼龙组。结论足量雾化吸入布地奈德8 mg/d能够明显改善AECOPD患者的肺功能、血气状况,与甲泼尼龙40 mg静滴作用相似,全身不良反应小,可作为全身激素的替代方法 。
作者 刘瑞清
出处 《中国医刊》 CAS 2012年第10期66-67,共2页 Chinese Journal of Medicine
  • 相关文献

参考文献6

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8243
  • 2Macintyre NR. Corticosteroid thrapy and chyonic obstructive pulmo- nary disease[J]. Respir Care, 2006, 51:289-296.
  • 3Vondrocek SF, Hemstreat BA. Retrospective evaluation of systemic corcosteroids for the management of acute exacerbations of chronic obstructive pulmonary disease. Am J Health Syst Pharm, 2006, 63:645-652.
  • 4余荣环,薄维娜,白春学.糖皮质激素治疗慢性阻塞性肺疾病急性加重的研究进展[J].国际呼吸杂志,2007,27(20):1566-1569. 被引量:14
  • 5Mahais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisonlone with placebo in the treatment of actue exacerbations of chronic obstructive pulmonary disease; a ran- domized controlled trial [ J]. AM J Respir Crit Care Med, 2002, 165:698-703.
  • 6Mirici A, Meral M, Akgue M. Comparison of the efficacy of neb- uised budesonide with parenteral corticosteoids in the treatment of chronic obstructive pulmonary disease[ J]. Clin Drug Invest, 2003, 23:56-62.

二级参考文献27

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:280
  • 2张星宇,郑翠侠,周巍,徐欣晖.雾化吸入布地奈德和静脉用泼尼松龙治疗慢性阻塞性肺病急性加重期疗效比较[J].中国老年学杂志,2006,26(8):1050-1051. 被引量:7
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8243
  • 4GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
  • 5Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
  • 6Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
  • 7冉丕鑫 王辰 姚婉贞 等.我国部分地区慢性阻塞性肺疾病流行病学研究[J].中华结核和呼吸杂志,2007,.
  • 8Celli BR, MacNee W, Agusti A, et al. Standards for diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J, 2004,23 : 932-946.
  • 9Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005, 1: CD001288.
  • 10Aaron SD, Vandemheen KL, Hehert P, et al. Outpatient oral prednlsone after emergency treatment of chronic obstruction pulmonary disease. N Engl J Med, 2003,348 :2618-2625.

共引文献8254

同被引文献53

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8243
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志,2007,46(3):254-261. 被引量:1798
  • 3Currie PJ,Seward JB,Chan KL. Continuous wave Dopplerdetermination of right ventrieular pressure a simultaneous Doppler catheterizationstudy in 127 patients[J].J Am Coil Cardiol,1985.750-756.
  • 4de Winter RJ,Stroobants A,Koch KT. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention[J].{H}American Journal of Cardiology,2004,(12):1481.
  • 5Karthikeyan G,Moncur RA,Levine O. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies[J].{H}Journal of the America College of Cardiology,2009,(17):1599.
  • 6Mehra MR,Maisel A. B-type natriuretic peptide in heart failure:diagnostic,prognostic,and therapeutic use[J].Crit Pathw Cardiol,2005,(01):10-20.
  • 7Mendes-Ribeiro AC. The role of exercise on L-arginine nitric oxide pathway in chronic heart failure[J].Open Biochem J,2009.55-65.
  • 8Leuchte HH,Baumgartner RA,Nounou ME. B rain natriuretic peptide is a prognostic parameter in chronic lung disease[J].{H}American Journal of respiratory and critical care medicine,2006,(07):744-750.
  • 9Leuchte HH,Neurohr C,Baumgartner R. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension[J].{H}American Journal of Respiratory and Critical Care Medicine,2004,(04):360-365.
  • 10陆慰萱;王辰.肺循环病学[M]{H}北京:人民卫生出版社,2007306.

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部